Across the board, there is no way to know about the right dose, purity, potential contaminants, and the impact of long-term use in people
The concentration varies by compounding pharmacy
Another factor is the severity and type of symptoms they are experiencing
High-purity production: Each peptide is produced to 99% purity with batch documentation available for qualified customers
They are offered together purely as a sourcing convenience, so a laboratory can obtain three distinct reference compounds in a single order
GHK-Cu will be voted on in a subsequent February 2027 meeting HHS has announced that GHK-Cu is expected to return to Category 1 (after being moved to Category 2 in September 2023), which would restore compounding access for injectable formulations. The dosing below draws from the per-component research and is reflected in the FDA review committee documents for each peptide, which aligns with PeptideFoxs previous research